Vetirus Pharmaceuticals Partners with Immune Propulsion to Advance Novel Immunotherapy for Companion Animal Cancer
18 Jun 2026
)
Vetirus Pharmaceuticals and Immune Propulsion have announced a strategic partnership to develop and commercialise IPVM-173. The proprietary IgG-degrading protease is being developed by Immune Propulsion's subsidiary ImmuneProVM and is designed to treat large mass tumours in companion animals. The same platform is also being advanced for human medicine.
By cleaving the hinge region of IgG antibodies, IPVM-173 redirects a natural bacterial strategy to paradoxically enhance the host's own anti-tumour immune response. Preclinical data demonstrate that IdeS-family enzymes can significantly boost the potency of monoclonal antibodies in oncology models, while naturally occurring anti-hinge antibodies in healthy subjects support effective tumour cell killing. IPVM-173 brings this platform to veterinary oncology as a simple, low-capital intervention with no anticipated increase in side effects.
Under the agreement, Vetirus will lead the development, regulatory advancement, and commercialisation of IPVM-173 exclusively for veterinary use. Immune Propulsion will continue advancing the platform for human medicine.
Robert N. Jordan, CEO of Vetirus Pharmaceuticals, said: “This collaboration marks an important step forward in veterinary oncology. By adapting this unique IgG-degrading technology, we can offer pets with large tumours a targeted treatment that works with the body’s natural defences. As a virtual tenant of LBIC with frequent office visits and invitations to LBIC events, we’ve valued being part of such a vibrant scientific ecosystem, and it’s exciting to see the progress we’re making in veterinary biotechnology.”
Vetirus has been a virtual client of LBIC since 2023.
Read the Full Press Release
Learn more:
Vetirus
Immune Propulsion
LBIC Virtual Client Packages